Clinical trial
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
NCT00165230 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165230 |
|---|---|
| Title | Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors |
| Official title | A Phase II Study of Thalidomide in Combination With Temodar in Patients With Metastatic Neuroendocrine Tumors |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumor |
| Intervention type | Drug |
| Interventions | Thalidomide, Temodar |
| Enrollment | 32 |
| Start date | May 1, 2002 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | Apr 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: